One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II.
Koster
A
A
Department of Anaesthesiology, Deutsches Herzzentrum Berlin, Berlin, Germany. koster@dhzb.de
Meyer
O
O
Fischer
T
T
Kukucka
M
M
Krabatsch
T
T
Bauer
M
M
Kuppe
H
H
Hetzer
R
R
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass; D002318:Cardiovascular Diseases / Q000601:surgery; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D006493:Heparin; D000077466:Tirofiban